Keywords: Boehringer Ingelheim, telmisartan, GlaxoSmithKline, Votrient, FDA approval, myocardial infraction, kidney cancer

US FDA clears two indications for Boehringer Ingelheim’s telmisartan and GSK’s Votrient for renal cancer

Article | 20 October 2009

Print This

German independent drug major Boehringer Ingelheim says that the US Food and Drug Administration has approved a new indication for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in